The vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths each year, has been approved by the UK's health regulator, according to GSK.The Medicines and Healthcare products Regulatory Agency (MHRA) approved GSK's Arexvy shot for active immunisation against RSV lower respiratory tract disease in adults 60 years and older, according to the company.RSV usually causes cold-like symptoms, but it is a leading cause of pneumonia in children and the elderly.Since the virus's discovery in 1956, efforts to develop a vaccine have been hampered by the virus's complex molecular structure and safety concerns with previous vaccine attempts.Arexvy has recently received approval from US and European regulators.
, CDSCO.jpg)
